CA-RAMBUS
Today Rambus Inc. (NASDAQ:RMBS) announced a comprehensive mobile payments platform to enhance payment security, reduce operational costs and increase revenue for retailers. The Rambus Unified Payment Platform securely converts and manages digital value to enable consumers to pay with credit, points and coupons in a single transaction, and transform how they shop and pay.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170227005329/en/
“Our Unified Payment Platform is based on a bank-proven foundation from our Bell ID acquisition, utilizing tokenization and card provisioning technology that is in use among the largest banks and payment networks worldwide,” said Dr. Ron Black, president and CEO of Rambus. “Our new platform extends this offering to the retailer, enabling them to incorporate payments and manage digital currencies inside a single app to realize an enhanced frictionless shopping experience.”
Overview of Rambus Unified Payment Platform
The Unified Payment Platform consists of these primary components: 1) the Digital Value Manager, 2) Retail Wallet Engine, 3) a white-label retail app and 4) optional modules to support credit/debit cards, gift cards, loyalty points and coupons.
| 1) | The Digital Value Manager – the core of the Unified Payment Platform – allows retailers to connect multiple third-party service providers and convert various forms of digital value into a unified “currency” that can be managed in a value store. | |
| 2) |
The secure Retail Wallet Engine software enables full integration with mobile payment products, including a white-label app, and features digital card enrollment, card provisioning and tokenization. The Retail Wallet Engine can be upgraded to include integration with Virtual Point of Sale (VPOS) capabilities and inventory management to enable one-click pay and auto-pay creating a truly frictionless consumer experience. |
|
| 3) | The white-label app software allows retailers to get their branded app quickly to market. The app can be fully integrated with a suite of products, providing consumers with all-in-one access to the retailer’s unified digital wallet and value-added services. | |
| 4) | Customizable modules that provide retailers and merchant acquirers the ability to securely connect to third-party services, convert different types of digital value to a unified currency, and manage gift card, loyalty and coupon services in-house. |
- A credit/debit card module that enables retailers to add a credit or debit card and using tokenization for secure access to digitize physical cards into a single wallet.
- A gift card module that allows consumers to add or purchase gift cards, redeem gift cards, reload, provide balance inquiry or transfer gift card values.
- A loyalty module that tracks new and existing loyalty cards, adds points on purchase, supports payment with points and adds bonus points to incentivize users to buy or select products.
- A coupon module that adds and redeems coupons, which enables retailers to push coupons to consumers in store or in virtual carts.
Enabling a Frictionless Shopping Experience
The Unified Payment Platform provides retailers with enhanced security, reduced cost and increased revenue. By using tokenization, the risk of card on file fraud is reduced by replacing key account information with temporary data. The Retail Wallet Engine enables in-aisle check-out options to lower overhead costs and reduce the number of POS terminals. The platform also helps increase revenue by allowing retailers to more easily engage in cross- or up-sell opportunities with integrated loyalty points and coupons. In addition, this facilitates direct access to detailed shopping data, allowing retailers, banks and merchant acquirers to offer a personalized shopping experience and more effectively compete in a crowded marketplace.
For consumers, the platform provides an effortless experience by unifying multiple units of value—including credit/debit, gift cards, loyalty points and coupons—into a single mobile app, along with digitized receipts and transaction history of purchases.
For more information about our Unified Payment Platform, please visit www.rambus.com/unifiedpayment .
About Rambus Security Division
The Rambus Security Division is dedicated to providing a secure foundation for a connected world. Integrating technologies from Cryptography Research, Bell ID and Ecebs, our innovative solutions span areas including tamper resistance, network security, mobile payment, smart ticketing and trusted transaction services. Our technologies protect nearly nine billion licensed products annually, providing secure access to data and creating an economy of digital trust between our customers and their customer base. Additional information is available at rambus.com/security .
About Rambus Inc.
Rambus creates innovative hardware and software technologies, driving advancements from the data center to the mobile edge. Our chips, customizable IP cores, architecture licenses, tools, software, services, training and innovations improve the competitive advantage of our customers. We collaborate with the industry, partnering with leading ASIC and SoC designers, foundries, IP developers, EDA companies and validation labs. Our products are integrated into tens of billions of devices and systems, powering and securing diverse applications, including Big Data, Internet of Things (IoT), mobile, and consumer platforms. At Rambus, we are makers of better. For more information, visit rambus.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170227005329/en/
Contact:
Rambus
Agnes Toan, 408-462-8905
Senior Manager, Corporate
Communications
atoan@rambus.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom